Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of CAR-T in Hematological Malignancies
NCT05618041Recruiting
- Sponsor
- Senlang Bio
- Start
- Sep 2022
- Primary completion
- Sep 2027
- Countries
- 1
01
Overview
Open-label, single-arm trial in acute lymphoblastic leukemia (ALL), lymphoma and multiple myeloma (MM), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Started Sep 2022; status: recruiting.
02
Conditions
acute lymphoblastic leukemia (ALL)lymphomamultiple myeloma (MM)
Beyond the preview
Go deeper on NCT05618041.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05618041.